Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04213885 · ClinicalTrials.gov registry record · Phase 2
Safety and Effectiveness of the PXL Platinum 330 System for Corneal Collagen Cross-Linking in Eyes With Corneal Thinning Position
A Phase 2 study of Keratoconus, Unstable and Bacterial Keratitis, sponsored by Eye Specialists of Indiana.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT04213885: Completed Phase 2 study of Keratoconus, Unstable and Bacterial Keratitis, sponsored by Eye Specialists of Indiana.
NCT04213885 is a Phase 2 study of Keratoconus, Unstable and Bacterial Keratitis that has completed, run by Eye Specialists of Indiana. The registered enrollment target is 12 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04213885, a Phase 2 study of Keratoconus, Unstable and Bacterial Keratitis, has completed, sponsored by Eye Specialists of Indiana.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine whether the Peschke PXL-330 is safe and effective in the treatment of corneal thinning conditions.
Primary Outcome
Average keratometry across the anterior topography of the cornea computed by a validated Scheimpflug topographer
Conditions Studied
Interventions
- COMBINATION_PRODUCT PXL 330 Platinum device/Riboflavin
Study Locations (1)
Indiana
- Eye Specialists of Indiana - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2020-05-04 |
| Est. Completion | 2024-08-05 |
| Phase | Phase 2 |
What the finished NCT04213885 record still lists
NCT04213885 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% lower).
The record links to 3 conditions, with Keratoconus, Unstable appearing as the primary indexed condition, and to 1 intervention - of which PXL 330 Platinum device/Riboflavin is the first listed.
NCT04213885 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT04213885 about?
NCT04213885 is a clinical study titled "Safety and Effectiveness of the PXL Platinum 330 System for Corneal Collagen Cross-Linking in Eyes With Corneal Thinning Position". To determine whether the Peschke PXL-330 is safe and effective in the treatment of corneal thinning conditions.
What is the current status of trial NCT04213885?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2020-05-04. Estimated completion is 2024-08-05.
What conditions does trial NCT04213885 study?
This clinical trial studies the following conditions: Keratoconus, Unstable, Bacterial Keratitis, Ectasia Corneal.
What interventions are being tested in trial NCT04213885?
The interventions under investigation include: PXL 330 Platinum device/Riboflavin (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04213885?
This trial is sponsored by Eye Specialists of Indiana, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04213885 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Keratoconus, Unstable
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04213885's enrollment target sits among peer trials
12 1948th of 2000 higher than 34 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI